(1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use
申请人:Janssen Pharmaceutica N.V.
公开号:US04859684A1
公开(公告)日:1989-08-22
Novel (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives, compositions containing the same, and methods of treating androgen dependent disorders in mammals.
A method for treating skin disorders in warm-blooded animals, said method comprising administering to said warm-blooded animals an effective amount of an appropriately substituted benzimidazole or benzotriazole which suppresses the metabolism of retinoids. Compositions comprising said compounds and an effective amount of a retinoid.
(1H-azol-1-ylmethyl)substituted quinoxaline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increased proliferation and/or abnormal differentiation of epithelial tissues.
Benzimidazoles useful in treating epithelial disorders
申请人:Janssen Pharmaceutica N.V.
公开号:US05342957A1
公开(公告)日:1994-08-30
A method for treating skin disorders in warm-blooded animals, said method comprising administering to said warm-blooded animals an effective mount of an appropriately substituted benzimidazole or benzotriazole which suppresses the metabolism of retinoids. Compositions comprising said compounds and an effective amount of a retinoid.
Use of benzimidazoles in the treatment of epithelial disorders
申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP0371559A2
公开(公告)日:1990-06-06
The use for the manufacture of a medicament for treating epithelial skin disorders of benzimidazole or benzotriazole of formula
wherein
-A¹=A²-A³=A⁴- is -CH=N-CH=CH-; -CH=N-CH=N-; or -CH=N-N=CH-;
R is hydrogen or C₁₋₆alkyl;
R¹ is hydrogen; C₁₋₁₀alkyl; C₃₋₇cycloalkyl; Ar¹ or Ar¹-C₁₋₆alkyl;
R² is hydrogen; C₃₋₇cycloalkyl; Ar¹; C₁₋₁₀alkyl; C₁₋₆alkyl substituted with Ar¹ or C₃₋₇cycloalkyl; hydroxy; C₁₋₁₀alkyloxy; C₁₋₆alkyloxy substituted with Ar¹ or C₃₋₇cycloalkyl; C₃₋₆alkenyloxy optionally substituted with Ar²; C₃₋₆alkynyloxy optionally substituted with Ar²; or Ar¹-oxy;
the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof; novel such compounds; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions; compositions containing the active ingredients (I) and/or (II) and a retinoic acid or a derivative thereof.